GLP-1R agonists’ type 2 diabetes and obesity market to reach $125 billion in 7MM by 2033: GlobalData Read more
GLP-1R agonist withdrawal effect on weight loss and cardiovascular risks remains unmet need: GlobalData Read more
Novo Nordisk Wegovy’s NHS access marks milestone in obesity treatment, but challenges remain: GlobalData Read more